Cantor outlines how to navigate the emerging Bitcoin treasury sector
David Jakeman, Vice President of Finance and Accounting at Chimerix Inc . (NASDAQ:CMRX), recently sold 300 shares of the company's common stock. The shares were sold on February 13 at a weighted average price of $4.532 per share, amounting to a total transaction value of $1,359. According to InvestingPro data, the stock is currently trading near its 52-week high of $4.65, having delivered an impressive return of over 317% in the past year. This sale was conducted to cover the tax liability incurred from the vesting of a restricted stock unit award granted on February 1, 2024. The shares were sold as part of an automatic sell-to-cover arrangement under Rule 10b5-1. Following the transaction, Jakeman holds 148,987 shares of Chimerix. InvestingPro analysis reveals 17 additional key insights about Chimerix, including detailed metrics on its financial health and market position. Get access to the comprehensive Pro Research Report covering what really matters about this $397.52M market cap company.
In other recent news, Chimerix has submitted Dordaviprone for accelerated approval and is currently awaiting a decision from the FDA, as reported by TD Cowen. Concurrently, H.C. Wainwright reaffirmed its Buy rating for Chimerix, highlighting the potential for a Priority Review Voucher and a Prescription Drug User Fee Act action date in the third quarter of 2025. The firm also projected sales of $6 million for Dordaviprone in the year of its potential launch.
In the biotech sector, TD Cowen outlined ten anticipated catalysts for the year 2025, including clinical trial data releases and regulatory milestones that could significantly influence investor interest. Companies such as ANAB, UTHR, QURE, ALKS, JAZZ, PRME, XENE, PTCT, RAPP, and CMRX are all expected to make significant strides in their respective programs.
In addition, Chimerix recently updated its Officer Severance Benefit Plan, extending its term for an additional three years from November 2024, with subsequent automatic one-year renewals. The updated plan outlines the terms and conditions applicable to the company's officers in the event of their departure, aligning with corporate governance practices. These are the recent developments in the company's trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.